ENOPH1 (enolase-phosphatase 1) is a bifunctional enzyme in the methionine salvage pathway that catalyzes the conversion of 2,3-diketo-5-methylthiopentyl-1-phosphate to acireductone intermediates 1. The enzyme functions as an oncogenic driver across multiple cancer types, promoting tumor cell proliferation, migration, and invasion. In glioma, ENOPH1 upregulation correlates with higher pathological grade and shorter overall survival, mechanistically activating the PI3K/AKT/mTOR signaling pathway through THEM4 regulation 12. Similarly, in hepatocellular carcinoma, ENOPH1 overexpression serves as an independent prognostic factor associated with increased metastatic potential and AKT pathway activation 3. In breast cancer, ENOPH1 promotes malignant behaviors through NF-κB pathway activation, with expression levels correlating with cancer stage and node metastasis status 4. Pan-cancer analysis reveals ENOPH1 upregulation across various tumor types, with high expression associated with poor survival outcomes and correlations with immune infiltration markers 5. Beyond oncology, ENOPH1 shows involvement in neuropsychiatric conditions, with genetic variation linked to anxiety and depression-related behaviors in mouse models 6. The enzyme also appears relevant in metabolic disorders, serving as a prognostic biomarker in polycystic ovary syndrome 7.